Infinity Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-09: Form 8-K; Period of report 2013-12-07; Description 8.01 Other Events; Details 8.01.
- 2013-11-07: Form 8-K; Period of report 2013-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-09-25: Form 8-K; Period of report 2013-09-25; Description 8.01 Other Events; Details 8.01.
- 2013-08-08: Form 8-K; Period of report 2013-08-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-12-09 | 8-K | 2013-12-07 | 8.01 Other Events | 8.01 On December 7 and December 8, 2013 we issued press releases announcing data from our Phase 1 study of IPI-145 in patients with advanced hematologic malignancies. | d639883d8k.htm |
| 2013-11-07 | 8-K | 2013-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2013, we issued a press release announcing our results for the quarter ended September 30, 2013 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d624485d8k.htm |
| 2013-09-25 | 8-K | 2013-09-25 | 8.01 Other Events | 8.01 On September 25, 2013 we issued a press release announcing topline data from our Phase 2 study of retaspimycin hydrochloride in combination with docetaxel in patients with non-small cell lung cancer. | d602891d8k.htm |
| 2013-08-08 | 8-K | 2013-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2013, we issued a press release announcing our results for the quarter ended June 30, 2013 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d582134d8k.htm |
| 2013-06-13 | 8-K | 2013-06-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.02 (e) At our Annual Meeting of stockholders held on June 11, 2013 (the “Annual Meeting”), our stockholders approved Amendment No. 4 to our 2010 Stock Incentive Plan, as amended (the “2010 Plan”), which amendment had previously been adopted by our Board of Directors, subject to shareholder approval, to increase the number of shares of our common stock that may be issued pursuant to awards granted under the 2010 Plan by an additional 1,485,000 shares. 8.01 Additionally, at our Annual Meeting our stockholders approved our 2013 Employee Stock Purchase Plan (the “2013 ESPP”) and the reservation of 250,000 shares for future issuance thereunder, which plan had previously been adopted by our Board of Directors, subject to shareholder approval. | d553902d8k.htm |
| 2013-06-04 | 8-K | 2013-06-02 | 8.01 Other Events | 8.01 On June 2, 2013 and June 3, 2013 we issued press releases announcing new data from our ongoing Phase 1, open-label, clinical trial of IPI-145, our potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies. | d549654d8k.htm |
| 2013-05-07 | 8-K | 2013-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2013, we issued a press release announcing our results for the quarter ended March 31, 2013 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d533857d8k.htm |
| 2013-04-12 | 8-K | 2013-04-10 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events | 1.01 On April 10, 2013, Infinity Pharmaceuticals, Inc. (the “Company,” “we,” “us” or “our”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC, acting as representatives of the underwriters named therein (collectively, the “Underwriters”), Beacon Company and Rosebay Medical Company L.P. (collectively, the “Selling Shareholders”), and Purdue Pharma L.P. (“PPLP”), an associated company of the Selling Shareholders, relating to an underwritten public offering of 10,000,000 shares (the “Shares”) of our common stock, par value $0.001 per share (the “Common Stock”). 1.02 On April 11, 2013, the Company entered into a letter agreement with the Selling Shareholders and PPLP (the “Letter Agreement”), pursuant to which, contingent upon the sale by the Selling Shareholders of all of their shares of Common Stock in the public offering referred to in Item 1.01 of this Current Report on Form 8-K (the “Public Offering”), including the shares subject to the over-allotment option, the securities purchase agreement, dated July 17, 2012, that the Company entered into with the Selling Shareholders and PPLP, as amended by that certain letter agreement, dated April 9, 2013, that the Company entered into with the Selling Shareholders and PPLP (the “Securities Purchase Agreement”), will terminate. 8.01 We issued press releases on April 9, 2013 and April 11, 2013 announcing the commencement of the Public Offering and the pricing of the Public Offering, respectively. | d520232d8k.htm |
| 2013-04-10 | 8-K | 2013-04-09 | 1.01 Entry into a Material Definitive Agreement | 1.01 On April 9, 2013, we entered into a letter agreement (the “Letter Agreement”) with our stockholders Beacon Company and Rosebay Medical Company L.P. (collectively, the “Selling Stockholders”), and Purdue Pharma L.P. (“PLPP”), an associated company of the Selling Stockholders, pursuant to which the parties have agreed that, effective upon the public announcement of a proposed underwritten offering of shares of our common stock held by the Selling Stockholders, including shares transferred to the Selling Stockholders by PPLP, which proposed offering was publicly announced on April 9, 2013, and contingent upon the sale of shares of our common stock by the Selling Stockholders in the proposed offering: (i) we have waived the existing lock-up restrictions set forth in the securities purchase agreement we entered into with the Selling Stockholders and PPLP on July 17, 2012, (the “2012 Purchase Agreement”), but only with respect to the shares of our common stock sold by the Selling Stockholders in the proposed offering; (ii) with respect to any shares of our common stock that are held by the Selling Stockholders and PPLP after this offering, (the “Remaining Shares”), the Selling Stockholders and PPLP have agreed that, with respect to the Remaining Shares, they will not exercise, in connection with our next offering of capital stock, certain “piggyback” registration rights that we granted to them pursuant to the 2012 Purchase Agreement; and (iii) any such Remaining Shares will be subject to a lock-up between us and the Selling Stockholders and PPLP through the six-month anniversary of the execution of the underwriting agreement in connection with the proposed offering, and the Selling Stockholders and PPLP agree, if so requested by the Company, the managing underwriters, the placement agents or the initial purchasers, as the case may be, pursuant to the 2012 Purchase Agreement, to execute a lock-up agreement, placement agents or other initial purchasers in any offering of our capital stock that commences on or before December 31, 2013. | d519543d8k.htm |
| 2013-04-09 | 8-K | 2013-04-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On April 3, 2013, Christopher M. Lindblom, our Vice President, Accounting and Finance, who also served as our principal accounting officer, informed our company that he will be resigning from his position effective May 3, 2013. | d518861d8k.htm |
| 2013-03-07 | 8-K | 2013-03-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On March 6, 2013, Patrick P. Lee informed our company that he will not stand for re-election to our Board of Directors (the “Board”) at our 2013 annual meeting of stockholders to be held on June 11, 2013. | d498812d8k.htm |
| 2013-03-05 | 8-K | 2013-03-05 | 2.02 Results of Operations and Financial Condition | 2.02 On March 5, 2013, we issued a press release announcing our results for the year ended December 31, 2012 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d496936d8k.htm |
| 2013-02-12 | 8-K | 2013-02-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (e) On February 6, 2013, the Compensation Committee of the Board of Directors of Infinity Pharmaceuticals, Inc. (the “Company”), approved the Infinity Pharmaceuticals, Inc. Executive Severance Benefits Plan (the “Plan”), effective February 6, 2013. | d482709d8k.htm |
| 2013-01-07 | 8-K | 2013-01-07 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2012, the Company announced on January 7, 2013, that it expects to report that it had approximately $327 million in cash, cash equivalents and available-for-sale securities as of December 31, 2012. 7.01 From time to time, the Company intends to conduct meetings with third parties in which its current corporate slide presentation is presented. 8.01 On January 7, 2013, the Company issued a press release announcing its 2013 business goals and financial guidance. | d462841d8k.htm |